OS Therapies OSTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by OS Therapies in its filing.
Tagged under the XBRL concept us-gaap:Cash.
The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about OS Therapies's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OS Therapies's cash & equivalents?
- OS Therapies (OSTX) reported cash & equivalents of $917.55K in Q1 2026.
- How has OS Therapies's cash & equivalents changed year-over-year?
- OS Therapies's cash & equivalents decreased by 69.1% year-over-year, from $2.97M to $917.55K.
- What is the long-term trend for OS Therapies's cash & equivalents?
- Over 3 years (2022 to 2025), OS Therapies's cash & equivalents has grown at a 16.3% compound annual growth rate (CAGR), from $171.48K to $269.83K.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.